Scholar Rock Holding Corp - Asset Resilience Ratio
Scholar Rock Holding Corp (SRRK) has an Asset Resilience Ratio of 20.13% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Scholar Rock Holding Corp's Asset Resilience Ratio has changed over time. Check SRRK capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Scholar Rock Holding Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Scholar Rock Holding Corp (SRRK) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $82.86 Million | 20.13% |
| Total Liquid Assets | $82.86 Million | 20.13% |
Asset Resilience Insights
- Good Liquidity Position: Scholar Rock Holding Corp maintains a healthy 20.13% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Scholar Rock Holding Corp Industry Peers by Asset Resilience Ratio
Compare Scholar Rock Holding Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Scholar Rock Holding Corp (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Scholar Rock Holding Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 54.62% | $259.40 Million | $474.92 Million | -2.64pp |
| 2023-12-31 | 57.25% | $178.08 Million | $311.04 Million | -1.96pp |
| 2022-12-31 | 59.21% | $212.09 Million | $358.17 Million | +46.02pp |
| 2021-12-31 | 13.19% | $40.16 Million | $304.44 Million | -33.34pp |
| 2020-12-31 | 46.53% | $180.67 Million | $388.31 Million | -15.16pp |
| 2019-12-31 | 61.69% | $121.14 Million | $196.38 Million | +28.28pp |
| 2018-12-31 | 33.41% | $60.58 Million | $181.34 Million | +30.98pp |
| 2017-12-31 | 2.43% | $1.50 Million | $61.64 Million | -52.48pp |
| 2016-12-31 | 54.91% | $18.00 Million | $32.78 Million | -- |
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to deve… Read more